Pilot study to assess the effect of enzyme-rich malt extract (Juvia) in the treatment of irritable bowel syndrome

Ateria Health Ltd0 个研究点目标入组 9 人开始时间: 2023年5月10日最近更新: 2024年7月8日

适应症

试验速览

暂无简介。

•1. Aged 18-65 years
•2. Current symptoms of IBS (abdominal pain and altered bowel habit) ROME IV criteria
•3. Prepared to take ERME (JUVIA) for the duration (taste test available for the patient)
•4. Normal full blood count within the last 12 months (from medical notes if available)
•5. Previous calprotectin (from medical notes if available) <80.ug/g
•6. Previous tissue transglutaminase (tTG) (from medical notes if available)
•7. Positive for malfermentation as decided by IBS Questionnaire Score
•8. Registered with a GP and consent to GP being informed

•1. Pregnant, planning to become pregnant or lactating
•2. Diabetic (or other co-morbidity that the CI considers inappropriate)
•3. On a restrictive diet or unwilling or unable to change diet
•4. Current medication (e.g. opiates) that may influence bowel symptoms (at the discretion of the CI)
•5. Antibiotics in the previous 6 weeks
•6. Other gastrointestinal disease (e.g. coeliac, Crohn’s disease or Ulcerative colitis )
•7. Significant gastrointestinal surgery (this will be a clinical decision and any patient who has had a surgical procedure that would change the mechanics of gut function would be excluded)
•8. Involved in other gastroenterology research project or other interventional study that would affect results

发起方

Ateria Health Ltd